180 related articles for article (PubMed ID: 32651695)
1. Racial Disparity in Pancreatoduodenectomy for Borderline Resectable Pancreatic Adenocarcinoma.
Molina G; Clancy TE; Tsai TC; Lam M; Wang J
Ann Surg Oncol; 2021 Feb; 28(2):1088-1096. PubMed ID: 32651695
[TBL] [Abstract][Full Text] [Related]
2. [Analysis on the clinical therapeutic effects of arterial first approach pancreatoduodenectomy in the treatment of borderline resectable pancreatic adenocarcinoma].
Jin G; Zheng KL; Guo SW; Shao Z; Liu C; Shi XH; Liu RD; Bai SJ; Jiang H; Bian Y; Hu XG
Zhonghua Wai Ke Za Zhi; 2017 Dec; 55(12):909-915. PubMed ID: 29224265
[No Abstract] [Full Text] [Related]
3. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
4. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
5. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
[TBL] [Abstract][Full Text] [Related]
6. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
7. Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study.
Ravikumar R; Sabin C; Abu Hilal M; Bramhall S; White S; Wigmore S; Imber CJ; Fusai G;
J Am Coll Surg; 2014 Mar; 218(3):401-11. PubMed ID: 24484730
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of local recurrence after pancreaticoduodenectomy for borderline resectable pancreatic head cancer with neoadjuvant chemotherapy: Can the resection level change after chemotherapy?
Kobayashi K; Ono Y; Sato S; Kato T; Oba A; Sato T; Ito H; Inoue Y; Takamatsu M; Saiura A; Takahashi Y
Surgery; 2023 May; 173(5):1220-1228. PubMed ID: 36424197
[TBL] [Abstract][Full Text] [Related]
9. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer.
Chawla A; Molina G; Pak LM; Rosenthal M; Mancias JD; Clancy TE; Wolpin BM; Wang J
Ann Surg Oncol; 2020 Apr; 27(4):1191-1200. PubMed ID: 31802297
[TBL] [Abstract][Full Text] [Related]
11. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
Kwon D; McFarland K; Velanovich V; Martin RC
Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
[TBL] [Abstract][Full Text] [Related]
12. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer.
Hartwig W; Gluth A; Hinz U; Koliogiannis D; Strobel O; Hackert T; Werner J; Büchler MW
Br J Surg; 2016 Nov; 103(12):1683-1694. PubMed ID: 27686238
[TBL] [Abstract][Full Text] [Related]
13. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
[TBL] [Abstract][Full Text] [Related]
14. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.
Brown KM; Siripurapu V; Davidson M; Cohen SJ; Konski A; Watson JC; Li T; Ciocca V; Cooper H; Hoffman JP
Am J Surg; 2008 Mar; 195(3):318-21. PubMed ID: 18308038
[TBL] [Abstract][Full Text] [Related]
15. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy.
Cools KS; Sanoff HK; Kim HJ; Yeh JJ; Stitzenberg KB
J Surg Oncol; 2018 Sep; 118(3):455-462. PubMed ID: 30114330
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic resection: a key component to reducing racial disparities in pancreatic adenocarcinoma.
Murphy MM; Simons JP; Hill JS; McDade TP; Chau Ng S; Whalen GF; Shah SA; Harrison LH; Tseng JF
Cancer; 2009 Sep; 115(17):3979-90. PubMed ID: 19514091
[TBL] [Abstract][Full Text] [Related]
17. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
[TBL] [Abstract][Full Text] [Related]
19. Initial Experience in the Treatment of "Borderline Resectable" Pancreatic Adenocarcinoma.
Busquets J; Fabregat J; Verdaguer H; Laquente B; Pelaez N; Secanella L; Leiva D; Serrano T; Cambray M; Lopez-Urdiales R; Ramos E
Cir Esp; 2017 Oct; 95(8):447-456. PubMed ID: 28992935
[TBL] [Abstract][Full Text] [Related]
20. Thirty-day complication rates do not differ by race among patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma.
Mitsakos AT; Dennis SO; Parikh AA; Snyder RA
J Surg Oncol; 2021 Mar; 123(4):970-977. PubMed ID: 33497474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]